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Abstract
Infection with high-risk human papillomaviruses (HR-HPVs, including HPV-16, HPV-
18, HPV-31) plays a central aetiologic role in the development of cervical carcinoma.
The transforming properties of HR-HPVs mainly reside in viral oncoproteins E6 and
E7. E6 protein degrades the tumour suppressor p53 and abrogates cell cycle check-
points. Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an oncoprotein
that is involved in the carcinogenesis of many human malignancies. Our previous
data showed that CIP2A was overexpressed in cervical cancer. However, the regula-
tion of CIP2A by HPV-16E6 remains to be elucidated. In this study, we demon-
strated that HPV-16E6 significantly up-regulated CIP2A mRNA and protein
expression in a p53-degradation-dependent manner. Knockdown of CIP2A by siRNA
inhibited viability and DNA synthesis and caused G1 cell cycle arrest of 16E6-
expressing cells. Knockdown of CIP2A resulted in a significant reduction in the
expression of cyclin-dependent kinase 1 (Cdk1) and Cdk2. Although CIP2A has been
reported to stabilize c-Myc by inhibiting PP2A-mediated dephosphorylation of
c-Myc, we have presented evidence that the regulation of Cdk1 and Cdk2 by CIP2A
is dependent on transcription factor B-Myb rather than c-Myc. Taken together, our
study reveals the role of CIP2A in abrogating the G1 checkpoint in HPV-16E6-
expressing cells and helps in understanding the molecular basis of HPV-induced
oncogenesis.
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1 | INTRODUCTION
Human papillomavirus (HPV) is a small DNA virus that replicates in
the stratified layers of skin and mucosa and is one of the most com-
mon sexually transmitted infections. The high-risk HPV type infec-
tions are associated with cervical carcinoma, which is one of the
leading causes of cancer death in women worldwide.1 In addition,
HPV infections are linked to more than 50% of other anogenital
cancers and cancers of the oesophagus.2 Although tobacco and alco-
hol are responsible for most head and neck squamous cell carcino-
mas (HNSCCs), there is evidence for a causal association between
HPV infections and HNSCCs. Despite a steady decrease in the num-
ber of overall HNSCCs cases in the past decades, the incidence of
oropharyngeal cancer has increased significantly.3 Notably, in the
meantime, the HPV DNA detection rate has increased from 16.3%
to 71.7% in oropharyngeal cancer.4
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Viral oncogenes have provided significant insights into important
biological activities. HPV oncogenes E6 and E7 are consistently
expressed in HPV-positive cervical cancers,5 and the sustained
expression of these genes is essential for the maintenance of the
transformed state of HPV-positive cells.6 E6 and E7 proteins pro-
mote the degradation of the tumour suppressors p53 and retinoblas-
toma protein (pRb), respectively, thus modulating multiple biological
functions including immortalization of primary cells, transformation
of mouse fibroblasts, tumorigenesis in animals, abrogation of cell
cycle checkpoints and chromosomal instability.7-9 The ability of high-
risk HPV E6 protein to degrade p53 is thought to be a primary
mechanism in inducing cellular transformation.
Cancerous inhibitor of PP2A (CIP2A) is an oncoprotein that was
first identified as an endogenous physiological inhibitor of tumour
suppressor protein phosphatase 2A (PP2A), a serine/threonine phos-
phatase.10 CIP2A is believed to execute its oncogenic functions
mainly through stabilizing c-Myc by inhibiting PP2A dephosphoryla-
tion of c-Myc serine 62 (S62).10 Various independent studies have
found that CIP2A is overexpressed in many types of human carcino-
mas, including breast, lung, gastric and hepatocellular cancers. In
addition to the role of CIP2A in promoting cellular transformation
and cancer aggressiveness, CIP2A is also associated with a high
tumour grade (for a review see Ref.11). CIP2A is related to a poor
patient prognosis and may be applied as a prognosis biomarker in
evaluating the risk of tumour metastasis. In addition, it is overex-
pressed in 70% of most solid malignancies samples, while it is rarely
expressed in normal tissues, which makes CIP2A a possible thera-
peutic target (for a review see Ref.12). Although the oncogenic role
of CIP2A in human malignancies has been well elucidated, how it
modulates cell proliferation and cell cycle remains largely unknown.
We have recently demonstrated that CIP2A is overexpressed
and positively associated with HPV-16E7 in cervical cancer tissues
and cells, and the expression of CIP2A is correlated with tumour
grade.13 However, as another important oncoprotein encoded by
HPV, how 16E6 protein regulates CIP2A and the role of CIP2A in
16E6-expressing cells remain unclear. In this report, we detected the
mRNA and protein expression of CIP2A in 16E6-expressing primary
human keratinocytes and explored the role of CIP2A in cell prolifera-
tion and G1 checkpoint regulation. We showed that HPV-16E6 pro-
tein up-regulated CIP2A by degrading p53 in 16E6-expressing cells
and that CIP2A facilitated the G1/S transition by modulating Cdk1
and Cdk2 proteins in a B-Myb–dependent manner.
2 | MATERIALS AND METHODS
2.1 | Cell culture and plasmids
Primary human keratinocytes (PHKs) were derived from neonatal
human foreskins collected from the University of Massachusetts
Hospital. PHKs were cultured on mitomycin-treated J2-3T3 mouse
fibroblast feeder cells in F-medium plus 5% foetal bovine serum
(FBS) with all supplements as described previously.14 To alleviate the
concern that PHKs have very low transfection efficiencies and
transfection usually causes G1 arrest, we use human telomerase
reverse transcriptase-expressing retinal pigment epithelium (RPE1)
cells expressing HPV-16E6 for the siRNA experiments. RPE1 cells
were originally obtained from Clontech15 and maintained in a 1:1
dilution of DMEM (Dulbecco’s modified Eagle’s medium) and Ham’s
F12 medium. The HPV-16–positive cervical cancer cell line SiHa was
purchased from the American Type Culture Collection (ATCC) and
maintained in DMEM. All media were supplemented with 100 U/mL
penicillin and 100 lg/mL streptomycin. All cells were grown in a
humidified 5% CO2 atmosphere at 37°C.
Primary human keratinocytes and RPE1 cells stably expressing
HPV-16E6 or F2V (Phe-2 to Val mutation), an E6 mutant defective
in p53 degradation or empty pBabe-puromycin vector, were estab-
lished by retrovirus-mediated infection. To ensure a high percentage
of cells that expressed 16E6, F2V or contained the Babe vector,
PHKs and RPE1-derived cell lines were maintained with puromycin
and used within 8 passages.
The pCDNA3 WT B-Myb (#25965) plasmid was purchased from
addgene.
2.2 | RNA extraction, RT-PCR and real-time
quantitative RT-PCR (qRT-PCR)
Total cellular RNA extraction was performed with the RNeasy mini
kit (Qiagen). RNA was then reverse-transcribed into cDNA with an
iScript cDNA synthesis kit (Bio-Rad). The cDNA samples were sub-
jected to PCR amplification with the primers described previously16:
HPV-16E6, For: 50-CTGCAATGTTTCAGGACCCA-30,
Rev: 50-CCTAATTAACAAATC-30.
b-actin, For: 50-TGGCATTGCCGACAGGATGCAGAA-30,
Rev: 50-CTCGTCATACTCCTGCTTGCTGAT-30.
b-Actin was used as a control for RNA loading and reverse tran-
scription efficiency.
Quantitative RT-PCR of CIP2A and cell cycle-related proteins
were performed as described previously.13 Glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) oligos were used as a control. Primer
pairs used for qRT-PCR were as follows:
CIP2A, For: 50-GAACAGATAAGAAAAGAGTTGAGCATT-30,
Rev: 50-CGACCTTCTAATTGTGCCTTTT-30;
Cdk1, For: 50-TTTTCAGAGCTTTGGGCACT-30,
Rev: 50-AGGCTTCCTGGTTTCCATTT-30;
Cdk2, For: 50-CAAGCTGCTGGATGTCATTC-30 ,
Rev: 50-AGCAGCTGGAACAGATAGCTCT-30;
Cdk4, For: 50-GCATCCCAATGTTGTCCG-30 ,
Rev: 50-AGGCAGCCCAATCAGGTC-30;
Cdk6, For: 50-TCTTGCTCCAGTCCAGCTAC-30,
Rev: 50-AGCAATCCTCCACAGCTCTG-30;
cyclin A2, For: 50-GAAGACGAGACGGGTTGCA-30 ,
Rev: 50-AGGAGGAACGGTGACATGCT-30;
cyclin B1, For: 50-AACTTTCGCCTGAGCCTATTTT-30 ,
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Rev: 50-TTGGTCTGACTGCTTGCTCTT-30;
cyclin D1, For: 50-CCGTCCATGCGGAAGATC-30,
Rev: 50-ATGGCCAGCGGGAAGAC-30;
cyclin E1, For: 50-GGATGTTGACTGCCTTGA-30,
Rev: 50-CACCACTGATACCCTGAAA-30; and
GAPDH, For: 50-GCACCGTCAAGGCTGAGAAC-30.
Rev: 50-GCCTTCTCCATGGTGGTGAA-30.
The relative expression was defined by the comparative Ct value.
2.3 | Western blot
Protein extracts were prepared in lysis buffer [10 mmol/L of Tris-
HCl (pH 7.4), 1% SDS, 1.0 mmol/L of sodium orthovanadate and
protease inhibitors]. Fifty micrograms of protein from each cell lysate
was denatured and separated by SDS-PAGE and transferred onto a
PVDF membrane. Membranes were probed with primary antibodies
specific for the following proteins: Cdk1 (BD Biosciences, 610038),
p21 (BD Biosciences, 610233); CIP2A (Novus Biologicals, NB100-
68264); B-Myb (sc-725), Cdk2 (sc-6248), Cdk4 (sc-260), Cdk6 (sc-
177), cyclin A2 (sc-751), cyclin B1 (sc-752), cyclin D1 (sc-718), cyclin
E1 (sc-198), c-Myc (sc-764), p53 (sc-126) and GAPDH (all from
Santa Cruz Biotechnology, sc-25778); and phospho-c-Myc (phospho
S62, Abcam, ab51156), HPV-16/18E6 (Abcam 70) and b-tubulin
(Sigma-Aldrich, T4026). Horseradish peroxidase (HRP)-conjugated
antimouse or anti-rabbit IgG (Santa Cruz Biotechnology) was used as
secondary antibodies. An enhanced chemiluminescence kit (ECL,
Pierce, USA) was used for detection.
ImageJ was used for the analysis of the grey values of the Wes-
tern blot bands. We first opened the file and defined the individual
sample as a rectangular box in which the band was fitted as tight as
possible; then, we clicked the “analyze-measure” and obtained the
grey value. The same box was used to measure all of the bands in
one file. The grey values of the corresponding loading control
(GAPDH/b-tubulin) were acquired following the same procedure.
The grey value of the protein of interest was divided by the grey
value of the corresponding loading control to get the relative value
of each band. The relative value of the first band of the protein of
interest in each image was set as “1,” and the relative values of the
other bands were divided by the relative value of the first band to
obtain a ratio, and the ratio was the “final relative value” of the
band. When Western blot experiments were repeated 3 times, we
obtained 3 ratios. These ratios were used for the calculation of mean
and SD values.
2.4 | Small interfering RNA and cell transfection
Chemically modified small interfering RNA (siRNA) oligonucleotides
against CIP2A have been described previously,13 and the sequences
of siRNA targeting CIP2A, B-Myb or HPV-16E6 (siRNA 209) are as
follows:
CIP2A siRNA, 50-CUGUGGUUGUGUUUGCACUTT-30,
B-Myb siRNA, 50-GAUCUGGAUGAGCUGCACU-30 , described in
Ref.17;
HPV-16E6 siRNA 209, 50-UCCAUAUGCUGUAUGUGAU-30,
described in Ref.18
A scrambled siRNA was synthesized for use as the control.
Retinal pigment epithelium or SiHa cells were seeded in 6-cm
dishes to ensure 30%-50% confluence at the time of transfection
and cultured in medium without antibiotics for 24 hours. siRNAs
were transfected into cells at a final concentration of 20 nmol/L
using Lipofectamine RNAiMAX (Invitrogen). For knockdown analysis,
cells were harvested 48 hours after transfection, and protein levels
were analysed by Western blot. CIP2A was knocked down approxi-
mately 70% after siRNA transfection, which was close to the level
expressed in the Babe vector cells. For cell cycle analysis, 36 hours
after transfection, cells were treated with bleomycin, incubated for
an additional 24 hours and harvested.
2.5 | Cell viability assay
The cell viability assay was assessed by use of the Cell Counting Kit
8 (CCK-8, Dojindo, Japan) following the manufacturer’s protocol.
2.6 | FACS analysis
For cell cycle analysis, RPE1 or SiHa cells were treated with PBS or
10 lg/mL bleomycin for 24 hours. Cells were harvested, fixed in
70% ethanol at 4°C overnight and stained with 50 lg/mL propidium
iodide (PI) supplemented with 70 lg/mL DNase-free RNAse A for
30 minutes at room temperature and analysed by flow cytometry.
The 5-bromo-20-deoxyuridine (BrdU, BD Biosciences) labelling
experiment was performed according to the manufacturer’s recom-
mendations. Immunofluorescent cells were analysed by use of FCS
Express software. All flow cytometric experiments were repeated at
least 3 times.
2.7 | Luciferase assay
The human Cdk1 and Cdk2 promoter-luciferase constructs—pGL3-
Cdk1 and pGL3-Cdk2—were purchased from Biosune. The renilla
luciferase control plasmid was purchased from Promega.
To evaluate whether B-Myb regulates the transcription of Cdk1
and Cdk2, RPE1 cells were cotransfected with the Cdk1 or Cdk2
promoter-luciferase constructs and renilla luciferase control plasmid
together with the B-Myb siRNA plasmid. Cells were harvested
after 48 hours, and luciferase activity was measured with the dual-
luciferase reporter assay system following the manufacturer’s
recommendations.
2.8 | Statistical analysis
All data are expressed as the means and standard deviations (SD).
Statistical analyses were based on nonparametric tests and
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performed with SPSS for Windows software, version 12.0. In all
analyses, P ≤ .05 was deemed significant.
3 | RESULTS
3.1 | High-risk HPV E6 up-regulates CIP2A in a
p53-degradation-dependent manner
To explore the mechanism by which E6 regulates CIP2A, we utilized
retrovirus-mediated successive infection to establish PHKs express-
ing wild-type HPV-16E6. The ability to promote the degradation of
p53 protein has been suggested as a mechanism by which E6 pro-
tein from the high-risk HPV types exhibits oncogenic activities, so a
16E6 mutant-F2V (Phe-2 to Val mutation) that does not degrade
p53 yet retains 16E6 activities for immortalization of HMECs was
constructed as we previously described.19 The expression of HPV-
16E6 and F2V mRNAs was confirmed by RT-PCR with 16E6 primers
(Figure 1A), while no expression of 16E6 mRNA was observed in the
Babe vector cells. The expression of 16E6 and F2V proteins was
confirmed using an HPV E6 antibody (Figure 1B). Both p53 and its
target p21 protein expression levels were decreased in 16E6-expres-
sing PHKs, while in the 16E6 mutant F2V-expressing cells, both p53
and p21 proteins remained nearly the same as in Babe vector cells
(Figure 1B).
We then examined CIP2A protein and mRNA levels in PHKs
expressing HPV-16E6. We showed that the CIP2A protein level was
significantly up-regulated (approximately 2.7-fold; P < .01) by HPV-
16E6 (Figure 1C,D). In addition, the CIP2A mRNA level was elevated
approximately 6.7-fold (P < .001) in PHKs expressing 16E6 (Fig-
ure 1E). However, there were no significant differences in CIP2A
protein or mRNA expression between F2V-expressing PHKs and
Babe vector cells, which indicates that the up-regulation of CIP2A
by HPV-16E6 is p53-degradation–dependent.
3.2 | Depletion of CIP2A inhibits cell viability and
DNA replication in 16E6-expressing cells
It has been reported that CIP2A promotes cell proliferation (for a
review see Ref.12). To explore the role of CIP2A in cellular prolifera-
tion of 16E6-expressing cells, small interfering RNA (siRNA) specific
to CIP2A that was previously shown to effectively down-regulate
CIP2A expression was used.13 We have constructed HPV-16E6–
expressing RPE1 cells and confirmed the expression of 16E6 in these
cells previously.20 Similar to what we have observed in PHKs, CIP2A
protein expression was up-regulated in RPE1 cells expressing 16E6
(Figure 2A). Depletion of CIP2A with siRNA efficiently decreased the
CIP2A protein level in 16E6-expressing cells. As HPV-16E6 degrades
p53, the steady-state level of p53 is low in 16E6-expressing cells.
Knockdown of CIP2A further reduced the expression of p53 protein
(Figure 2B). A CCK-8 assay was performed to determine whether
CIP2A had any effect on cell viability. As shown in Figure 2C, CIP2A
knockdown inhibited the viability of 16E6-expressing RPE1 cells.
F IGURE 1 Induction of CIP2A mRNA and protein expression by HPV-16E6 in PHKs. A, mRNA expression of HPV-16E6 in PHKs
expressing 16E6 and F2V using b-actin as a loading control. B, Protein levels of HPV-16E6, p53 and p21 in PHKs expressing 16E6 and F2V.
Expression of GAPDH was used as a loading control. A representative of 2 independent experiments is shown. C, HPV-16E6 expression leads
to increased protein expression of CIP2A in PHKs. Data from a representative of 3 experiments are shown. D, Data from 3 experiments are
summarized. E, Relative CIP2A mRNA expression was determined by qRT-PCR in the above cells. Data from 3 experiments are summarized.
The mean and standard deviation (SD) of 3 independent experiments are shown. Babe, pBabe-puromycin vector. *, P < .05; **, P < .01; and
***, P < .001
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To examine the effect of CIP2A on S phase entry and DNA repli-
cation in 16E6-expressing cells, a 5-bromo-20-deoxyuridine (BrdU)
incorporation approach was applied to mark cells in S phase. Com-
pared with scrambled siRNA, knockdown of CIP2A by siRNA signifi-
cantly decreased the number of BrdU-positive cells (24.0% vs
41.7%) (P < .01) (Figure 2D,E). Therefore, CIP2A silencing hindered
cells entering S phase and impaired DNA synthesis in HPV-16E6–
expressing cells.
3.3 | CIP2A knockdown diminishes the ability of
16E6 protein to abrogate the G1 checkpoint
Flow cytometry was performed to investigate the effect of CIP2A on
cell cycle distribution. It is well known that HPV-16E6 abrogates the
G1 cell cycle checkpoint (for a review see Ref.8). However, the role of
CIP2A in regulating the G1 checkpoint in 16E6-expressing cells has
not previously been investigated. For this, we treated cells with bleo-
mycin, a radiomimetic agent inducing DNA breaks and causing both
G1 and G2 arrest.21 CIP2A siRNA increased the proportion of cells
that arrested at the G1/S transition (71.7  3.7% vs 55.2  2.6%,
P < .01), which showed more cells accumulated at the G1 peak
(Figure 3A,B). Less accumulation of cells at S phase was also observed
(5.8  1.4% vs 12.7  1.2%, P < .01). Upon induction of DNA dam-
age by bleomycin, considerably fewer (18.5  2.8% vs 29.9  3.1%,
P < .01) 16E6-expressing cells were arrested in G1 phase compared to
the Babe vector cells, which indicated that 16E6 bypassed bleomycin-
induced G1 arrest. Notably, inhibition of CIP2A by siRNA severely
diminished the ability of 16E6 to abrogate the G1 checkpoint by caus-
ing more cells to arrest in G1 phase (28.6  2.0% vs 17.7  4.9%,
P < .01). These results indicate a role for CIP2A in bypassing the DNA
damage-induced G1 cell cycle checkpoint in 16E6-expressing cells.
3.4 | CIP2A knockdown down-regulates Cdk1 and
Cdk2 proteins
Cell cycle progression is monitored by several checkpoints, among
which the G1 checkpoint is very important, as it determines whether
cells enter S phase and initiate DNA replication. To explore how
CIP2A modulates the G1 checkpoint, we examined the expression of
cell cycle-related proteins including Cdk4, Cdk6, Cdk1, and Cdk2 and
their associated cyclin partners—cyclin D1, cyclin A2, cyclin B1 and
cyclin E1. In addition to Cdk2, which was proposed to be a major
regulator in S phase entry, the protein level of the mitotic Cdk-Cdk1
was also markedly reduced with CIP2A knockdown (P < .05) (Fig-
ure 4A,B). The cyclin partner of Cdk1-cyclin B1 decreased signifi-
cantly as well (P < .05). In contrast, no significant alterations were
observed in the expression of structurally and functionally similar
Cdk4 and Cdk6 proteins as well as their main partner cyclin D1 after
CIP2A silencing. Meanwhile, no decrease in cyclin E1 and cyclin A2
was observed in CIP2A knockdown cells (Figure 4A,B). We then
F IGURE 2 Inhibition of CIP2A by siRNA impeded cell viability and DNA synthesis in HPV-16E6–expressing cells. A, Elevated expression of
CIP2A protein in 16E6-expressing RPE1 cells. B, Western blot analysis of CIP2A and p53 proteins after transfection with scrambled siRNA
(siCon) or CIP2A siRNA (siCIP2A) for 48 h. A representative of 3 independent experiments is shown. C, Cell viability assay of RPE1-16E6 cells
with CIP2A knockdown. D, Representative flow cytometry of BrdU staining profiles is shown. E, The mean and SD of BrdU-positive cells from
3 experiments are summarized. **, P < .01.
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treated the cells with bleomycin and detected the expression of cell
cycle-related proteins, and similar alterations, such as Cdk1, Cdk2
and cyclin B1 expression decreasing significantly after CIP2A knock-
down, were observed (Figure 4A,B). As Cdk2 and Cdk1 are the key
factors to drive the G/S transition, these results hint that CIP2A
might bypass the G1 checkpoint by regulating Cdk1 and Cdk2 pro-
teins in 16E6-expressing cells.
We performed qRT-PCR to detect the mRNA levels of all cell
cycle-related genes. Interestingly, knockdown of CIP2A did not cause
significant changes in mRNA levels of these cell cycle regulators (Fig-
ure 4C), which suggests that CIP2A does not affect the transcription
of these genes and that the regulation of Cdk1 and Cdk2 by CIP2A
may be post-transcriptional.
3.5 | Regulation of Cdk1 and Cdk2 by CIP2A
depends on B-Myb, instead of c-Myc
The transcription factor c-Myc is a basic helix-loop-helix leucine zip-
per protein that is involved in cell proliferation, cell cycle progres-
sion, metabolism and malignant transformation through targeting of
downstream genes.22 We speculated that cell cycle regulation by
CIP2A may depend on c-Myc as CIP2A stabilizes c-Myc by prevent-
ing dephosphorylation on S62 of c-Myc. Surprisingly, both the pro-
teins of c-Myc and phospho-S62-Myc remained unaltered following
CIP2A silencing in HPV-16E6–expressing cells (Figure 5A). Interest-
ingly, CIP2A knockdown caused an obvious decrease in the steady-
state level of transcription factor B-Myb (Figure 5A). We further
examined the expression of B-Myb and c-Myc in PHKs expressing
HPV-16E6. As shown in Figure 5B, HPV-16E6 greatly up-regulated
the expression of B-Myb, while neither the expression of c-Myc nor
phospho-S62-Myc increased in 16E6-expressing cells. Similar results
were observed in 16E6-expressing RPE1 cells (Figure 5C). Thus, the
expression of CIP2A and B-Myb but not c-Myc was positively corre-
lated in 16E6-expressing cells. B-Myb was reported to transactivate
the transcription of Cdk1.23 To clarify the regulation of Cdk1 and
Cdk2 by B-Myb in 16E6-expressing cells, we further knocked down
B-Myb with a specific siRNA, and correspondingly, markedly
decreased expression of Cdk1 and Cdk2 was observed (Figure 5D).
In addition, knockdown of B-Myb caused reductions in CIP2A and
p53 proteins, which suggests that there may be positive feedback
between CIP2A and B-Myb. We further determined the effect of B-
Myb on the transcription of Cdk1 and Cdk2-luciferase constructs.
Figure 5E shows that the activities of the Cdk1 and Cdk2 promoters
were clearly reduced when B-Myb was knocked down (P < .05).
Moreover, knockdown of B-Myb caused G1 arrest (83.8  8.1% vs
67.8  5.1%, P < .05), and there were fewer cells in S phase (2.20%
vs 6.36%). When treated with bleomycin, B-Myb knockdown caused
G1 arrest (66.5  3.8% vs 34.8  4.7%, P < .001) (Figure 5F,G).
F IGURE 3 Silencing CIP2A caused G1
arrest in 16E6-expressing cells. A, Flow
cytometric analysis of 16E6-expressing
cells transfected with CIP2A siRNA for
36 h, treated with PBS or 10 lg/mL
bleomycin for 24 h and then stained with
PI. G1, S and G2 phases are indicated.
Data from a representative of 4
experiments are shown. B, Quantification
of percentages G1 phase and S phase cells.
Data from 4 experiments are summarized.
*, P < .05; **, P < .01
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Furthermore, we introduced a plasmid encoding B-Myb in CIP2A
knockdown cells, and the overexpression of B-Myb rescued the
expression of Cdk1 and Cdk2 (Figure 5H). Taken together, these
experiments suggest that the regulation of Cdk1 and Cdk2 by CIP2A
may rely on the transcription factor B-Myb.
To further verify the regulation and function of CIP2A in cervical
cancer cells, we introduced HPV-16–positive SiHa cells. HPV-16E6–
specific siRNA was reported to be effective and specific when trans-
fected into SiHa cells.18 The decreased 16E6 protein and elevated
p53 protein indicated that HPV-16E6 was efficiently knocked down
(Figure 6A). Our data showed that CIP2A was reduced after 16E6
knockdown. However, we noticed that the decrease in CIP2A was
not dramatic, and we propose that this is mainly because HPV E7
also has the ability to up-regulate CIP2A.13 Furthermore, we showed
that B-Myb might be a downstream target of CIP2A as CIP2A silenc-
ing greatly inhibited the expression of B-Myb in SiHa cells
(Figure 6B). As expected, the levels of Cdk1 and Cdk2 proteins
decreased correspondingly. Flow cytometric analysis showed that
CIP2A silencing caused more cells to arrest in G1 phase
(71.9  5.0% vs 56.9  5.6%, P < .05) and fewer cells to enter S
phase (9.46% vs 13.0%) (Figure 6C,D). Moreover, CIP2A silencing
enhanced bleomycin-induced G1 arrest, which showed a more accu-
mulated G1 phase (65.8  8.1% vs 49.7  3.1%, P < .05) in SiHa
cells. The data further hint that CIP2A may be involved in the G1
checkpoint by regulating Cdk1 and Cdk2 in a B-Myb–dependent
manner in cervical cancer cells.
4 | DISCUSSION
By retrovirus-mediated overexpressing of HPV-16E6 and E6 mutant-
F2V, on the one hand, we showed that 16E6 significantly increased
CIP2A mRNA and protein expression in a p53-degradation–depen-
dent manner. On the other hand, knockdown of CIP2A caused a
reduction in the expression of p53 in HPV-16E6-expressing cells.
Although the interaction between p53 and CIP2A needs to be further
F IGURE 4 Silencing CIP2A caused decreased Cdk1 and Cdk2 proteins in 16E6-expressing cells. A, Western blot analysis of CIP2A, Cdk4,
Cdk6, cyclin D1, Cdk1, Cdk2, cyclin B1, cyclin A2 and cyclin E1 protein levels in cells expressing HPV-16E6 transfected with CIP2A siRNA and
then treated with PBS or 10 lg/mL bleomycin for 24 h. A representative of 3 independent experiments is shown. B, Quantification of all cell
cycle-related proteins. Data from 3 experiments are summarized. C, Relative mRNA levels of all cell cycle-related genes determined by qRT-
PCR. Data from 3 experiments are summarized. *, P < .05; **, P < .01
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F IGURE 5 Regulation of Cdk1 and Cdk2 by CIP2A is dependent on B-Myb rather than c-Myc. A, Western blot analysis of CIP2A, c-Myc,
phospho-S62-Myc and B-Myb protein levels in 16E6-expressing cells after CIP2A knockdown. b-Tubulin was used as a loading control. B,
Protein levels of B-Myb, c-Myc and phospho-S62-Myc in 16E6-expressing PHKs and (C) RPE1 cells. D, Protein levels of B-Myb, Cdk1 and
Cdk2, CIP2A and p53 in 16E6-expressing cells after B-Myb knockdown with siRNA. Data from a representative of 3 experiments are shown.
E, Knockdown of B-Myb down-regulates Cdk1 and Cdk2 luciferase reporter activities. RPE1 cells were cotransfected with the Cdk1 or Cdk2
promoter-luciferase constructs and renilla luciferase control plasmid together with B-Myb siRNA plasmid. Cells were harvested after 48 h, and
lysates were assayed for luciferase activity. F, Flow cytometric analysis of 16E6-expressing cells transfected with B-Myb siRNA treated with
PBS or bleomycin. G1, S and G2 phases are indicated. A representative flow cytometry of 3 independent experiments is shown.
G, Quantification of percentages G1 phase cells. Data from 3 experiments are summarized. H, Western blot analysis of B-Myb, Cdk1 and Cdk2
in B-Myb–overexpressing CIP2A knockdown cells. Data from a representative of 3 experiments are shown. *, P < .05; ***, P < .001
F IGURE 6 Inhibition of Cdk1 and Cdk2 by CIP2A knockdown in cervical cancer SiHa cells caused G1 arrest. A, Western blot analysis of
16E6, p53 and CIP2A after HPV-16E6 knockdown in cervical cancer SiHa cells. B, Protein expression of CIP2A, B-Myb, Cdk1 and Cdk2 in
SiHa cells after CIP2A knockdown. Data from a representative of 3 experiments are shown. C, Flow cytometric analysis of SiHa cells with
CIP2A knockdown treated with PBS or bleomycin. A representative flow cytometry of 3 independent experiments is shown. D, Quantification
of percentages G1 phase cells. Data from 3 experiments are summarized. *, P < .05
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investigated, our finding is in accordance with that of previous stud-
ies. One study demonstrated that in human breast cancer tissues,
CIP2A mRNA expression was positively correlated with p53 muta-
tions; in addition, in breast cancer mouse models with p53 depletion,
CIP2A protein expression was induced.24 Another study showed that
after treatment with doxorubicin, CIP2A expression was increased in
MDA-MB231 (mutant p53 breast cancer cell line) cells and decreased
in MCF-7 (wild-type p53 breast cancer cell line) cells, which demon-
strated that cells with mutant p53 have higher CIP2A expression.25
Notably, treatment with p53 activator molecules resulted in a reduc-
tion in CIP2A expression in breast cancer cells.26 Taken together, our
data and results from these investigations strongly suggest a negative
association between p53 and CIP2A proteins, and further research
will focus on the underlying molecular basis.
Genomic instability is an important prerequisite and hallmark of
carcinogenesis. Cell cycle progression is monitored at several cell
cycle checkpoints by regulating the expression and activity of cyclins
and Cdks, whose defects contribute to genomic instability.27 The G1
checkpoint is the first to determine whether cells enter the S phase
and initiate DNA replication. The G1 checkpoint is mainly regulated
by Cdk2/cyclin E-cyclin A complexes by phosphorylation of pRb.28
Upon DNA damage caused by exposure to genotoxic agents such as
UV or chemicals, p53 is activated via multiple mechanisms and inac-
tivates the Cdk2/cyclin E-cyclin A complexes by activating transcrip-
tion of the Cdk inhibitor p21, resulting in pRb hypophosphorylation
and G1 cell cycle arrest.29 Because of the central role p53 plays in
G1 checkpoint control and the efficient degradation of p53 by high-
risk HPV E6 protein, it is reasonable that HPV-16E6 abrogates the
G1 cell cycle checkpoint.30 However, whether CIP2A is involved in
the abrogation of the G1 checkpoint in HPV-16E6–expressing cells
is unclear. Our data showed that knockdown of CIP2A by siRNA
abrogated the ability of 16E6 to bypass the G1 checkpoint, thus
proving the function of CIP2A in G1 checkpoint regulation.
Cdk2 was believed to be a major regulator and was essential in S
phase entry. However, an increasing number of studies have shown
that Cdk1 plays a vital role in the maintenance of cell cycle progres-
sion. A previous report showed that Cdk1 can substitute for Cdk2
during the G1/S transition.31 Moreover, a study of Cdk2/Cdk3/
Cdk4/Cdk6-knockout mice demonstrated that Cdk1 binds all cyclins
and drives the whole cell cycle progression.32 Our data showed that
both Cdk2 and Cdk1 function in the G1/S transition and reduced
Cdk2 and Cdk1 by CIP2A knockdown lead to G1 arrest. Our results
reveal that CIP2A facilitates the G1/S transition by regulating Cdk1
and Cdk2.
c-Myc is a transcriptional factor implicated in control of cell pro-
liferation as well as a variety of cellular regulatory processes. The
regulation of c-Myc by HPV-16E6 is conflicting. HPV-16E6 has been
reported to activate and up-regulate the expression of c-Myc protein
in a p53-dependent manner.33 However, one study showed that
HPV-16E6 did not up-regulate c-Myc, and c-Myc was not required
for the activation of telomerase.34 Moreover, other report showed
in vitro degradation of c-Myc protein by 16E6.35 Therefore, the acti-
vation or degradation of c-Myc by 16E6 may be cell-specific or
merely reflect the rate of cell proliferation under distinct environ-
mental conditions. Our studies could not find a significant up-regula-
tion of c-Myc in 16E6-expressing PHKs, which is consistent with the
results found in HFK (human foreskin keratinocytes, also named
PHK).34 More importantly, CIP2A silencing did not repress either c-
Myc or phospho-S62-Myc expression, which indicates that the regu-
lation of the G1 checkpoint by CIP2A is c-Myc–independent.
B-Myb is a transcription factor with specific DNA-binding activ-
ity.36 Previous studies have shown that B-Myb is overexpressed in
cervical cancers.37 Importantly, the expression of B-Myb mRNA
peaks during the G1/S phase transition.38 In addition, overexpression
of B-Myb bypassed p53-induced G1 arrest.39 Notably, B-Myb was
reported to bind to the Cdk1 promoter and activate the expression
of Cdk1.23 It is well documented that B-Myb was up-regulated in
HPV E7-expressing cells.40 However, the expression and function of
B-Myb in 16E6-expressing cells have not been reported. Our data
demonstrated that B-Myb protein was up-regulated by HPV-16E6,
while CIP2A knockdown caused inhibition of B-Myb. Although B-
Myb is involved in p53-induced G1 arrest abrogation,39,41 the under-
lying mechanism is not fully understood. We showed that B-Myb
was required for CIP2A to regulate Cdk1 and Cdk2. Our results sug-
gest that positive regulation of Cdk1 and Cdk2 by B-Myb con-
tributes to bypassing the G1 checkpoint in 16E6-expressing cells.
Future research will focus on the precise regulation of B-Myb by
CIP2A.
We demonstrated that CIP2A is up-regulated by HPV-16E6 in a
p53-dependent manner. CIP2A is essential to abrogate the G1 cell
cycle checkpoint by modulating Cdk1 and Cdk2 expression in HPV-
16E6–expressing cells. Furthermore, a luciferase assay showed that
the regulation of Cdks by CIP2A in 16E6-expressing cells depends
on the transcription factor B-Myb rather than c-Myc. Our results
reveal a specific role of CIP2A in HPV-16E6–mediated regulation of
G1/S cell cycle progression. Previous study demonstrated that
CIP2A protein was specifically expressed in cervical cancer tissues
and was undetectable in normal adjacent cervical tissues.42 Our labo-
ratory found that CIP2A protein was overexpressed in cervical can-
cer and high grade of cervical intraepithelial neoplasia (CIN), CIN III,
which was the key step from the precancerous to invasive cancer,
but not in normal cervical, CINI or CINII tissues.13 This expression
pattern indicates that CIP2A has a clinical prominence in the devel-
opment of cervical cancer and makes CIP2A to be a potential diag-
nostic biomarker. In addition, CIP2A mutant mouse models showed
no obvious abnormality in mouse development and viability.43
Therefore, the expression specificity and limited toxicity indicate that
CIP2A inhibitors may be a hopeful therapeutic strategy for treatment
of cervical cancer. However, much effort is needed for translational
medicine and clinical application of targeting CIP2A for cervical can-
cer diagnosis and treatment.
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